In comments on the Centers for Medicare & Medicaid Services' advance notice of proposed rulemaking on the International Pricing Index model for Medicare Part B drugs, AHA commends the agency's willingness to address excessive growth in drug prices, but "given the amount of model specifics still to be determined, the anticipated operational burdens, as well as other logistical concerns, the AHA urges CMS to consider narrowing the scope of the program to a more targeted intervention than that described in the ANPRM." AHA's Dec. 27 comments and concerns focused on the ANPRM's impact on hospitals participating in the 340B Drug Pricing Program; regulatory and operational burden; payment reductions; and model vendors' fees and policies. The AHA noted that its primary concern is the model's interaction with the 340B program and asked CMS to hold 340B hospitals harmless under the model. AHA said it looks forward to working with CMS "to improve the IPI model."

Related News Articles

Headline
About 34 percent of uninsured U.S. adults did not take their medication as prescribed in 2017 in order to reduce their prescription drug costs, according to a…
Headline
Legislative proposals for a Medicare public option could negatively affect patient access to care and significantly reduce payments to hospitals, AHA Executive…
Headline
The Centers for Medicare & Medicaid Services today updated its Medicare and Medicaid drug spending dashboards with 2017 data.
Headline
The House Energy and Commerce Health Subcommittee today held a hearing to discuss seven bills aimed at increasing competition in the prescription drug market…
Headline
The Senate Special Committee on Aging today concluded a two-part hearing on the impact of rising prescription drug costs on seniors and potential policy…
Headline
Eight in 10 U.S. adults say prescription drug costs are “unreasonable,” and one in four say their prescription medicines are difficult to afford, according to…